Literature DB >> 20560017

Menopausal hormone therapy for cardiovascular protection--unfulfilled expectations.

Nanette K Wenger1.   

Abstract

Despite biologically plausible mechanisms of benefit and data from observational studies suggesting cardioprotection from menopausal hormone therapy, the results of randomized clinical trials in both healthy women and women with established coronary heart disease failed to show benefit and indeed imparted some harm. In 2009, menopausal hormone therapy is not indicated for the primary prevention of coronary heart disease or of cardiovascular disease. Prevention of cardiovascular disease in women should be addressed by the aggressive identification and modification of established cardiovascular risk factors. Much remains unknown about the mechanisms of menopausal hormone therapy action and the issue of whether there is a therapeutic window of opportunity for its use.

Entities:  

Mesh:

Year:  2009        PMID: 20560017     DOI: 10.1007/s12265-009-9117-6

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  13 in total

Review 1.  Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease.

Authors:  Linda L Humphrey; Benjamin K S Chan; Harold C Sox
Journal:  Ann Intern Med       Date:  2002-08-20       Impact factor: 25.391

Review 2.  Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update.

Authors:  Lori Mosca; Carole L Banka; Emelia J Benjamin; Kathy Berra; Cheryl Bushnell; Rowena J Dolor; Theodore G Ganiats; Antoinette S Gomes; Heather L Gornik; Clarissa Gracia; Martha Gulati; Constance K Haan; Debra R Judelson; Nora Keenan; Ellie Kelepouris; Erin D Michos; L Kristin Newby; Suzanne Oparil; Pamela Ouyang; Mehmet C Oz; Diana Petitti; Vivian W Pinn; Rita F Redberg; Rosalyn Scott; Katherine Sherif; Sidney C Smith; George Sopko; Robin H Steinhorn; Neil J Stone; Kathryn A Taubert; Barbara A Todd; Elaine Urbina; Nanette K Wenger
Journal:  J Am Coll Cardiol       Date:  2007-03-20       Impact factor: 24.094

3.  Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.

Authors:  M J Stampfer; G A Colditz
Journal:  Prev Med       Date:  1991-01       Impact factor: 4.018

4.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

5.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Authors:  Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

6.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Sally A Shumaker; Claudine Legault; Stephen R Rapp; Leon Thal; Robert B Wallace; Judith K Ockene; Susan L Hendrix; Beverly N Jones; Annlouise R Assaf; Rebecca D Jackson; Jane Morley Kotchen; Sylvia Wassertheil-Smoller; Jean Wactawski-Wende
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

7.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

Authors:  Deborah Grady; David Herrington; Vera Bittner; Roger Blumenthal; Michael Davidson; Mark Hlatky; Judith Hsia; Stephen Hulley; Alan Herd; Steven Khan; L Kristin Newby; David Waters; Eric Vittinghoff; Nanette Wenger
Journal:  JAMA       Date:  2002-07-03       Impact factor: 56.272

8.  Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors.

Authors:  Peter Collins; Lori Mosca; Mary Jane Geiger; Deborah Grady; Marcel Kornitzer; Messan G Amewou-Atisso; Mark B Effron; Sherie A Dowsett; Elizabeth Barrett-Connor; Nanette K Wenger
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Authors:  Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick
Journal:  JAMA       Date:  2008-03-05       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.